PL3548033T3 - Związki i sposoby ich stosowania - Google Patents

Związki i sposoby ich stosowania

Info

Publication number
PL3548033T3
PL3548033T3 PL17874657.4T PL17874657T PL3548033T3 PL 3548033 T3 PL3548033 T3 PL 3548033T3 PL 17874657 T PL17874657 T PL 17874657T PL 3548033 T3 PL3548033 T3 PL 3548033T3
Authority
PL
Poland
Prior art keywords
compounds
methods
Prior art date
Application number
PL17874657.4T
Other languages
English (en)
Polish (pl)
Inventor
Kiran Reddy
Gabriel Martinez Botella
Andrew Mark Griffin
Brian Edward Marron
Original Assignee
Praxis Precision Medicines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Precision Medicines, Inc. filed Critical Praxis Precision Medicines, Inc.
Publication of PL3548033T3 publication Critical patent/PL3548033T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL17874657.4T 2016-11-28 2017-11-28 Związki i sposoby ich stosowania PL3548033T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662427044P 2016-11-28 2016-11-28
US201762458306P 2017-02-13 2017-02-13
US201762552073P 2017-08-30 2017-08-30
PCT/US2017/063533 WO2018098499A1 (en) 2016-11-28 2017-11-28 Compounds and their methods of use

Publications (1)

Publication Number Publication Date
PL3548033T3 true PL3548033T3 (pl) 2025-06-02

Family

ID=62195384

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17874657.4T PL3548033T3 (pl) 2016-11-28 2017-11-28 Związki i sposoby ich stosowania

Country Status (13)

Country Link
US (3) US11629146B2 (enExample)
EP (2) EP4397308A3 (enExample)
JP (3) JP7105797B2 (enExample)
CN (2) CN116763791A (enExample)
AU (3) AU2017364901A1 (enExample)
BR (1) BR112019010880A2 (enExample)
DK (1) DK3548033T3 (enExample)
ES (1) ES2992063T3 (enExample)
FI (1) FI3548033T3 (enExample)
HU (1) HUE068842T2 (enExample)
PL (1) PL3548033T3 (enExample)
PT (1) PT3548033T (enExample)
WO (1) WO2018098499A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018098499A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
KR102809796B1 (ko) * 2018-05-30 2025-05-20 프락시스 프리시젼 메디신즈, 인크. 이온 채널 조절인자
EP3840733A4 (en) 2018-08-20 2022-07-20 Rogcon, Inc. ANTISENSE OLIGONUCLEOTIDES DIRECTED TO SCN2A FOR THE TREATMENT OF SCN1A ENCEPHALOPATHIES
EA202092908A1 (ru) * 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
WO2021039961A1 (ja) * 2019-08-30 2021-03-04 大日本住友製薬株式会社 縮環ピラゾール誘導体
BR112022010186A2 (pt) * 2019-11-26 2022-08-09 Praxis Prec Medicines Inc Moduladores de canal iônico
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
JP2023504038A (ja) * 2019-11-27 2023-02-01 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーターの製剤ならびにイオンチャネルモジュレーターの調製および使用の方法
JP2021195367A (ja) * 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
KR20240088848A (ko) * 2021-09-13 2024-06-20 베링거잉겔하임베트메디카게엠베하 사이클로프로필-(헤테로)아릴-치환된 에틸설포닐-피리딘 유도체
AU2023260468A1 (en) * 2022-04-26 2024-11-28 Praxis Precision Medicines, Inc. Treatment of neurological disorders
CN120641418A (zh) * 2022-10-07 2025-09-12 腾维治疗公司 化合物、组合物和方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4230705A (en) * 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
CA1080712A (en) * 1976-09-22 1980-07-01 Jay D. Albright Hypotensive agents
US4112095A (en) * 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
GB9507348D0 (en) * 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
JP2004532792A (ja) 2000-07-14 2004-10-28 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 神経障害を治療するためのイミダゾ［１，２−ａ］ピラジン
NZ544162A (en) * 2003-05-29 2008-09-26 Shire Llc Abuse resistant amphetamine compounds
CA2556404A1 (en) * 2004-02-18 2005-08-25 Banyu Pharmaceutical Co., Ltd. Nitrogenous fused heteroaromatic ring derivative
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
US20100088778A1 (en) 2005-06-16 2010-04-08 John Charles Mulley Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
ES2612377T3 (es) 2005-12-21 2017-05-16 Janssen Pharmaceutica N.V. Triazolopiridazinas como moduladores de tirosina cinasas
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
AU2009212254A1 (en) 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of Ranolazine for treating pain
WO2010053757A1 (en) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010056865A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Quinoline derivatives as ion channel modulators
BR122013027950A2 (pt) 2008-12-24 2019-12-10 BIAL PORTELA & Cª S A compostos farmacêuticos
JP5340798B2 (ja) 2009-05-07 2013-11-13 タイガースポリマー株式会社 地中埋設管の製造方法
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
EA025824B1 (ru) * 2009-07-27 2017-02-28 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
FR2953520B1 (fr) 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
EP2704573A4 (en) 2011-05-03 2014-10-15 Merck Sharp & Dohme AMINOMETHYL biaryl BENZOTRIAZOL DERIVATIVES
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (enExample) 2011-07-01 2018-04-28
EP2758053A1 (en) 2011-09-21 2014-07-30 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
BR112014006924B1 (pt) 2011-09-27 2020-10-06 Genfit Derivados de triazolopiridazinas 6-substituídas como agonistas de rev-erb
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
TWI574962B (zh) * 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
WO2014100764A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Methods of inhibiting prmt5
WO2014179492A1 (en) 2013-05-01 2014-11-06 Gilead Sciences, Inc. Combination therapy for the treatment of arrhythmias or heart failure
HRP20200854T1 (hr) 2013-06-21 2020-08-21 Zenith Epigenetics Ltd. Novi biciklički inhibitori bromodomene
WO2015026849A1 (en) 2013-08-19 2015-02-26 The Regents Of The University Of California Compounds and methods for treating an epileptic disorder
GB201321740D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EA029415B1 (ru) 2013-12-19 2018-03-30 Джилид Сайэнс, Инк. Производные 2-оксо-3,4-дигидро-2н-бензо[e][1,3]оксазина
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
AU2015271719A1 (en) * 2014-06-04 2016-12-01 Rugen Holdings (Cayman) Limited Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
ES2912073T3 (es) 2014-06-20 2022-05-24 Mitsubishi Chem Corp Policarbonatodiol, método para producir el mismo, y poliuretano producido usando el mismo
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
PE20161476A1 (es) 2014-06-26 2017-01-07 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona
JP2017001991A (ja) 2015-06-11 2017-01-05 大日本住友製薬株式会社 新規ベンズオキサゾロン化合物
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US20210188839A1 (en) 2016-11-28 2021-06-24 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
WO2018098499A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
KR102809796B1 (ko) 2018-05-30 2025-05-20 프락시스 프리시젼 메디신즈, 인크. 이온 채널 조절인자
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
BR112022010186A2 (pt) 2019-11-26 2022-08-09 Praxis Prec Medicines Inc Moduladores de canal iônico
JP2023504038A (ja) 2019-11-27 2023-02-01 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーターの製剤ならびにイオンチャネルモジュレーターの調製および使用の方法

Also Published As

Publication number Publication date
EP4397308A2 (en) 2024-07-10
AU2023282271A1 (en) 2024-01-18
AU2017364901A1 (en) 2019-06-13
BR112019010880A2 (pt) 2019-10-01
JP7105797B2 (ja) 2022-07-25
ES2992063T3 (es) 2024-12-09
US11629146B2 (en) 2023-04-18
CN116763791A (zh) 2023-09-19
CA3045121A1 (en) 2018-05-31
JP2022141773A (ja) 2022-09-29
EP4397308A3 (en) 2024-08-21
AU2025237912A1 (en) 2025-10-16
PT3548033T (pt) 2024-08-09
JP7495962B2 (ja) 2024-06-05
WO2018098499A1 (en) 2018-05-31
EP3548033A1 (en) 2019-10-09
DK3548033T3 (da) 2024-07-15
EP3548033A4 (en) 2020-09-09
US20250163068A1 (en) 2025-05-22
US20210188852A1 (en) 2021-06-24
US20230322790A1 (en) 2023-10-12
HUE068842T2 (hu) 2025-01-28
EP3548033B1 (en) 2024-04-10
CN110337295B (zh) 2023-06-09
JP2019535838A (ja) 2019-12-12
FI3548033T3 (fi) 2024-07-10
JP2024100974A (ja) 2024-07-26
CN110337295A (zh) 2019-10-15

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
IL276946A (en) Antiproliferative compounds and methods of use
ZA201905677B (en) Glycan-interacting compounds and methods of use
IL258768A (en) Compounds interacting with glycans and methods of use
PL3548033T3 (pl) Związki i sposoby ich stosowania
IL250415B (en) Antibodies against pd-l and methods of using them
EP3377070A4 (en) COMPOUNDS AND METHOD FOR THEIR USE
PL3218005T3 (pl) Związki oddziałujące z glikanami i sposoby ich zastosowania
PT3089971T (pt) Compostos e métodos de utilização
IL282482A (en) Variants of protoxin-II and methods of use
GB201514760D0 (en) Compounds and method of use
IL253234A0 (en) Methods for transdifferentiation and methods to use them
GB201609786D0 (en) Compounds and method of use
IL267671A (en) Pyrazolopyrimidine compounds and methods of their use
IL282508A (en) Variants of protoxin-II and methods of use
IL265955A (en) Therapeutic compounds and methods of using them
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201802134B (en) Therapeutic compounds and methods of use thereof
ZA201606450B (en) Compounds and their methods of use
IL261794A (en) Preparations and methods for using them
HK40092374A (zh) 聚糖相互作用化合物及使用方法
GB201403697D0 (en) Compounds and methods of use
ZA201606358B (en) Compositions of selenoorganic compounds and methods and methods of use thereof
HK1228198A1 (en) Compounds and their methods of use
GB201416797D0 (en) Contianer and method of use thereof